Journal of Carcinogenesis

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 20  |  Issue : 1  |  Page : 1-

Ten-year survival outcome of breast cancer patients in India


Patel Viral1, K Pavithran2, K Beena3, Ajil Shaji4, DK Vijaykumar5 
1 Department of Gynecological Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India
2 Department of Medical Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India
3 Department of Radiation Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India
4 Department of Cancer Registry, Amrita Institute of Medical Science, Kochi, Kerala, India
5 Amrita Centre for Breast Diseases, Amrita Institute of Medical Science, Kochi, Kerala, India

Correspondence Address:
D K Vijaykumar
Amrita Centre for Breast Diseases, Amrita Institute of Medical Sciences and Research Center, Kochi - 682 041, Kerala
India

INTRODUCTION: Breast cancer is the most frequently diagnosed cancer among women in India; however, there are no studies addressing long-term survival (10 years and above). This study sought to evaluate long-term oncological outcome among women with breast cancer treated with a curative intent. MATERIALS AND METHODS: This is a retrospective cohort analysis of 1301 breast cancer patients of all stages who had received primary treatment with curative intent from 2004 to 2010 at a single cancer institution of India. RESULTS: A total of 1301 breast cancer patients were available for final analysis. The median age was 51 years (range, 21–86 years). 70.25% of the patients had early breast cancer (EBC), 21.9% had locally advanced breast cancer, and 7.85% of the patients with de novo metastatic disease also underwent surgery. 56.5% of the patients had hormone-sensitive tumors, human epidermal growth factor receptor 2 over expression was seen in 17%, and triple-negative tumors accounted for 26.2% of the patients. The 5- and 10-year overall survival (OS) of the entire cohort was 79% and 66%, and the 5- and 10-year breast cancer-specific survival (BCSS) was 79% and 70%, respectively. OS and BCSS were 51% and 58%, respectively, at 15-year follow-up after primary cancer treatment. On multivariate analysis, the factors associated with prolonged survival were age ≤50 years, EBC, and treatment during the later period (2008–2010). CONCLUSION: Difference between OS and BCSS was found to have an increasing trend during 10–15-year follow-up, the difference being 4% at 10 years and 7% at 15 years. Age ≤50 years, early-stage disease at presentation, and primary cancer treatment in later years (2008–2010) were favorable predictors for 10-year survival.


How to cite this article:
Viral P, Pavithran K, Beena K, Shaji A, Vijaykumar D K. Ten-year survival outcome of breast cancer patients in India.J Carcinog 2021;20:1-1


How to cite this URL:
Viral P, Pavithran K, Beena K, Shaji A, Vijaykumar D K. Ten-year survival outcome of breast cancer patients in India. J Carcinog [serial online] 2021 [cited 2021 May 14 ];20:1-1
Available from: http://www.carcinogenesis.com/article.asp?issn=1477-3163;year=2021;volume=20;issue=1;spage=1;epage=1;aulast=Viral;type=0